7XSA image
Deposition Date 2022-05-13
Release Date 2023-05-10
Last Version Date 2024-11-06
Entry Detail
PDB ID:
7XSA
Title:
Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P2S-2E9 Fab
Biological Source:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.20 Å
R-Value Free:
0.28
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:P2S-2E9 Heavy chain
Chain IDs:A (auth: B), D (auth: H)
Chain Length:218
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:P2S-2E9 Light chain
Chain IDs:B (auth: C), E (auth: I)
Chain Length:215
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Spike protein S1
Gene (Uniprot):S
Chain IDs:C (auth: E), F (auth: J)
Chain Length:242
Number of Molecules:2
Biological Source:Severe acute respiratory syndrome coronavirus 2
Ligand Molecules
Primary Citation
Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants.
Nat.Immunol. 24 690 699 (2023)
PMID: 36914890 DOI: 10.1038/s41590-023-01449-6

Abstact

The omicron variants of SARS-CoV-2 have substantial ability to escape infection- and vaccine-elicited antibody immunity. Here, we investigated the extent of such escape in nine convalescent patients infected with the wild-type SARS-CoV-2 during the first wave of the pandemic. Among the total of 476 monoclonal antibodies (mAbs) isolated from peripheral memory B cells, we identified seven mAbs with broad neutralizing activity to all variants tested, including various omicron subvariants. Biochemical and structural analysis indicated the majority of these mAbs bound to the receptor-binding domain, mimicked the receptor ACE2 and were able to accommodate or inadvertently improve recognition of omicron substitutions. Passive delivery of representative antibodies protected K18-hACE2 mice from infection with omicron and beta SARS-CoV-2. A deeper understanding of how the memory B cells that produce these antibodies could be selectively boosted or recalled can augment antibody immunity against SARS-CoV-2 variants.

Legend

Protein

Chemical

Disease

Primary Citation of related structures